AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14689372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II infusion during telmisartan therapy (40-80 mg/day)
Number of subjects: 10
Study 14689372 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 10
Study 14689372 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan therapy (40-80 mg/day)
Number of subjects: 10
Study 10868708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler
Number of subjects: 72
Study 10868708 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Nebuhaler
Number of subjects: 72
Study 9183594 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 28
Study 1607733 — intervention group
Group type: EXPERIMENTAL
Intervention: HCR therapy (hyperthermo-chemoradiotherapy)
Number of subjects: 53
Study 1607733 — intervention group
Group type: COMPARATOR
Intervention: CR therapy (chemoradiotherapy without hyperthermia)
Number of subjects: 53
Study 3885454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (1600 mg) and Doxycycline (400 mg)
Number of subjects: 267
Study 3885454 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole (1600 mg) and Placebo
Number of subjects: 267
Study 30290817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin‐etoposide chemotherapy (maximum of six cycles)
Number of subjects: 250
Study 30290817 — intervention group
Group type: COMPARATOR
Intervention: Control group (250 controls)
Number of subjects: 250
Study 26228645 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (group P, n = 33)
Number of subjects: 64
Study 26228645 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (group V, n = 31)
Number of subjects: 64
Study 24865132 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once a day
Number of subjects: 1331
Study 24865132 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1331
Study 22583605 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvic external-beam radiation therapy of 50 Gy/25 fractions and high-dose-rate intracavitary brachytherapy of 24 Gy/4 fractions without chemotherapy
Number of subjects: 59
Study 20108006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 60
Study 20108006 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study 18316519 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 (500 mg, 1,000 mg, 2,000 mg for fasting; 1,000 mg for nonfasting)
Number of subjects: 0
Study 18316519 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246
Number of subjects: 0
Study 18316519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15944076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 28
Study 15944076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 12727125 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic control treatment
Number of subjects: 68
Study 12727125 — intervention group
Group type: COMPARATOR
Intervention: Panic control with in vivo exposure
Number of subjects: 68
Study 10975629 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA) plus contingent vouchers, n = 125
Number of subjects: 190
Study 10975629 — intervention group
Group type: COMPARATOR
Intervention: Control treatments, n = 65
Number of subjects: 190
Study 9366300 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CAVI (methotrexate, carboplatin, and vinblastine)
Number of subjects: 47
Study 9366300 — intervention group
Group type: COMPARATOR
Intervention: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 47
Study 1439854 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (YOH) ointment, 5 mg applied twice daily at the balanopreputial sulcus.
Number of subjects: 62
Study 1439854 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine delivered with cavernous bodies by a Controlled Transdermal Drugs Administration System (C.T.D.A.S.).
Number of subjects: 62
Study 3754043 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium YAG laser (Nd:YAG)
Number of subjects: 38
Study 3754043 — intervention group
Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 38
Study 29290089 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMX
Number of subjects: 20
Study 29290089 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 20
Study 29290089 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMs
Number of subjects: 20
Study 28815629 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxified alcohol-dependent patients (AUD)
Number of subjects: 410
Study 28815629 — intervention group
Group type: COMPARATOR
Intervention: Young adult social drinkers
Number of subjects: 410
Study 25075894 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique as described by Stevens (group A)
Number of subjects: 18
Study 25075894 — intervention group
Group type: COMPARATOR
Intervention: Technique modified from Paley (group B)
Number of subjects: 18
Study 24304605 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (600 mg of n-3 PUFA)
Number of subjects: 24
Study 24304605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (600 mg of n-3 PUFA)
Number of subjects: 24
Study 24304605 — intervention group
Group type: COMPARATOR
Intervention: Control (corn oil)
Number of subjects: 24
Study 21423000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosahexanoic acid daily)
Number of subjects: 90
Study 21423000 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90
Study 21423000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral fish oil
Number of subjects: 90
Study 18176174 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol administration during 1 year
Number of subjects: 16
Study 18176174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcitriol)
Number of subjects: 16
Study 16570433 — intervention group
Group type: EXPERIMENTAL
Intervention: Guan-moxibustion plus acupuncture
Number of subjects: 157
Study 16570433 — intervention group
Group type: COMPARATOR
Intervention: Suspended moxibustion plus acupuncture
Number of subjects: 157
Study 14563500 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal remedy (four tablets, three times a day for 30 days)
Number of subjects: 237
Study 14563500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets, three times a day for 30 days)
Number of subjects: 237
Study 10213724 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without a placebo arm
Number of subjects: 436
Study 10213724 — intervention group
Group type: COMPARATOR
Intervention: Trial with a placebo arm
Number of subjects: 436
Study 8724688 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement strategy (concierge service)
Number of subjects: 0
Study 8724688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8724688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 2 intervention
Number of subjects: 0
Study 8724688 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cycle 2)
Number of subjects: 0
Study 1684310 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD), 60 mg every 4 weeks
Number of subjects: 41
Study 1684310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 1684310 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD)
Number of subjects: 41
Study 7201100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (16 units per day for 10 days)
Number of subjects: 14
Study 7201100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7201100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin
Number of subjects: 14
Study 31261577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT) intervention
Number of subjects: 96
Study 31261577 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 28132685 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent or new-onset ASH
Number of subjects: 1691
Study 28132685 — intervention group
Group type: COMPARATOR
Intervention: No association with increased mortality
Number of subjects: 1691
Study 26564411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild propofol sedation
Number of subjects: 48
Study 26564411 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep propofol sedation
Number of subjects: 48
Study 24018576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession training over 10 days (9 adults/group) for older adults
Number of subjects: 30
Study 24018576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession training over 10 days (9 adults/group) for young adults
Number of subjects: 30
Study 24018576 — intervention group
Group type: COMPARATOR
Intervention: Control group of older adults (6 adults/group)
Number of subjects: 30
Study 24018576 — intervention group
Group type: COMPARATOR
Intervention: Control group of young adults (6 adults/group)
Number of subjects: 30
Study 20864613 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (n=250)
Number of subjects: 504
Study 20864613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=254)
Number of subjects: 504
Study 19408821 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual oral hygiene instruction
Number of subjects: 104
Study 19408821 — intervention group
Group type: EXPERIMENTAL
Intervention: Group oral hygiene instruction
Number of subjects: 104
Study 19408821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of individual and group oral hygiene instructions
Number of subjects: 104
Study 19408821 — intervention group
Group type: COMPARATOR
Intervention: No oral hygiene instruction (Control group)
Number of subjects: 104
Study 17696684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg) after pretreatment with placebo
Number of subjects: 18
Study 17696684 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum (4 mg) after pretreatment with 50 mg naltrexone
Number of subjects: 18
Study 15167602 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25 to 3.5 mg, single oral dose)
Number of subjects: 16
Study 15167602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11499124 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief preventive intervention
Number of subjects: 0
Study 11499124 — intervention group
Group type: COMPARATOR
Intervention: High-risk controls (normative comparison)
Number of subjects: 0
Study 9713029 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (25 mg/kg/d)
Number of subjects: 86
Study 9713029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7474673 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate as the sole phosphate-binding agent during sodium citrate infusion.
Number of subjects: 0
Study 7474673 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate as the sole phosphate-binding agent during calcium infusion.
Number of subjects: 0
Study 2128881 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 46
Study 2128881 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (follicle-stimulating hormone)
Number of subjects: 46
Study 387019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine
Number of subjects: 159
Study 29057579 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of daily Internet gaming (training group)
Number of subjects: 119
Study 29057579 — intervention group
Group type: COMPARATOR
Intervention: Non-gaming condition (training control group)
Number of subjects: 119
Study 29057579 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive Internet gamers
Number of subjects: 119
Study 28452622 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% cortical FDBA
Number of subjects: 66
Study 28452622 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% cancellous FDBA
Number of subjects: 66
Study 28452622 — intervention group
Group type: EXPERIMENTAL
Intervention: 50%/50% cortico-cancellous FDBA
Number of subjects: 66
Study 25881639 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment combined with topical cactus and aloe cold compresses
Number of subjects: 0
Study 25881639 — intervention group
Group type: COMPARATOR
Intervention: Massage treatment or cactus and aloe cold compresses alone
Number of subjects: 0
Study 25139884 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum calcium levels during follow-up (higher tertile of change: 0.52 ± 0.13 mg/dL)
Number of subjects: 77
Study 25139884 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-adjusted serum calcium analyzed as a continuous variable
Number of subjects: 77
Study 21785860 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 10
Study 21785860 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ng/kg/min iv epoprostenol
Number of subjects: 10
Study 21785860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19563665 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 221
Study 19563665 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 221
Study 17883462 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus loperamide (500 mg)
Number of subjects: 176
Study 17883462 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone (500 mg or 1000 mg)
Number of subjects: 176
Study 17883462 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 176
Study 14744822 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in water
Number of subjects: 99
Study 14744822 — intervention group
Group type: COMPARATOR
Intervention: Standard augmentation (amniotomy and intravenous oxytocin)
Number of subjects: 99
Study 14744822 — intervention group
Group type: COMPARATOR
Intervention: Standard augmentation
Number of subjects: 99
Study 12471288 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (low- and moderate-intensity, 25-50% HRR)
Number of subjects: 18
Study 12471288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 18
Study 10366085 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap with phacotrabeculectomy
Number of subjects: 44
Study 10366085 — intervention group
Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap with phacotrabeculectomy
Number of subjects: 44
Study 7656936 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1.2 mg) once daily via a Nebuhaler for 6 months
Number of subjects: 47
Study 7656936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2523653 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 800
Study 2523653 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 800
Study 1155428 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiometrics blood pressure recorder with broad, hard surrounding cuff
Number of subjects: 443
Study 1155428 — intervention group
Group type: COMPARATOR
Intervention: Standard cuff sizes selected according to recommended criteria (Baumanometer)
Number of subjects: 443
Study 31356973 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 544
Study 31356973 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 544
Study 31356973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVP and CT
Number of subjects: 544
Study 28071840 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 34
Study 28071840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25333246 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise program (land/aquatic activities, aerobic and muscular conditioning), 60 min on land and 50 min in water, three times per week, n = 101
Number of subjects: 342
Study 25333246 — intervention group
Group type: COMPARATOR
Intervention: Usual standard care, n = 156
Number of subjects: 342
Study 25333246 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise program
Number of subjects: 342
Study 23009672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Independence Program (HIP)
Number of subjects: 750
Study 23009672 — intervention group
Group type: COMPARATOR
Intervention: Usual home-care services
Number of subjects: 750
Study 23009672 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 150 from each group
Number of subjects: 750
Study 21463380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside tribochemical silica coating/silane coupling system (CoJet group)
Number of subjects: 24
Study 21463380 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (control group)
Number of subjects: 24
Study 21463380 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tribochemical silica coating/silane coupling system (Rocatec group)
Number of subjects: 24
Study 19231993 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-active ART
Number of subjects: 36
Study 17042769 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF administration from day +5 (arm A)
Number of subjects: 106
Study 17042769 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed, individually determined G‐CSF administration (arm B)
Number of subjects: 106
Study 17042769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm C)
Number of subjects: 106
Study 17042769 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF (arm A and B)
Number of subjects: 106
Study 15222820 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical retrieval practice
Number of subjects: 43
Study 11425416 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine (7.5 microg doses)
Number of subjects: 65
Study 11425416 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (30 microg doses)
Number of subjects: 65
Study 11425416 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine (30 microg doses)
Number of subjects: 65
Study 11425416 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine
Number of subjects: 65
Study 9246960 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose of 1.2 g Augmentin at induction of anesthesia
Number of subjects: 320
Study 9246960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 8042122 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interventions focused on individuals
Number of subjects: 0
Study 8042122 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level interventions focused on vulnerable communities
Number of subjects: 0
Study 2500137 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. immune globulin
Number of subjects: 50
Study 2500137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31846857 — intervention group
Group type: EXPERIMENTAL
Intervention: RANAS-based intervention
Number of subjects: 224
Study 31846857 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 224
Study 31515567 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based chin tuck against resistance exercise
Number of subjects: 37
Study 31515567 — intervention group
Group type: COMPARATOR
Intervention: Head-lift exercise
Number of subjects: 37
Study 28854884 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization program of drug prescribing consisting of a clinical medication review by a pharmacist, in collaboration with specialist physician of the geriatric/memory center and the referent physician.
Number of subjects: 302
Study 28854884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 302
Study 25277272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation therapy (ADT) with docetaxel
Number of subjects: 385
Study 25277272 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT) without docetaxel
Number of subjects: 385
Study 24100934 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of £15 (€17; $22) for each depot injection over a 12 month period
Number of subjects: 141
Study 24100934 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 141
Study 21734640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 192
Study 21734640 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate/dexamethasone
Number of subjects: 192
Study 19396507 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual in-line stabilization (MILS)
Number of subjects: 200
Study 19396507 — intervention group
Group type: COMPARATOR
Intervention: Control (optimal head position)
Number of subjects: 200
Study 16794160 — intervention group
Group type: COMPARATOR
Intervention: Metal cannula without anesthetic
Number of subjects: 89
Study 16794160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal cannula with paracervical anesthetic block
Number of subjects: 89
Study 16794160 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible balloon catheter
Number of subjects: 89
Study 12492745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 10 mg
Number of subjects: 371
Study 12492745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 371
Study 12492745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 371
Study 12492745 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 371
Study 11071030 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with posterior capsule rupture with or without vitreous loss (PCR +/‐ VL), n=192
Number of subjects: 2794
Study 11071030 — intervention group
Group type: COMPARATOR
Intervention: Patients with no complications, n=275
Number of subjects: 2794
Study 9288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 9288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg)
Number of subjects: 0